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Insulin resistance, a characteristic fea-
ture of type 2 diabetes, is associated
with central obesity, hypertension, dys-
lipidemia, and cardiovascular disease
(and death) (1). The mechanism of
insulin resistance is complex and
largely unknown. Both in animals and
in humans, however, insulin resistance
can be induced by lipid infusion. In a
recent issue of the JCI, Kim and col-
leagues presented new data on the
mechanisms responsible for the induc-
tion of insulin resistance by lipids. In
an elegant set of experiments, they
show that activation of IKK-β is
important in fat-induced insulin (2).
High-dose salicylate prevents the fat-
induced defects in insulin signaling.
Based on these findings, the authors
suggest that “salicylates represent a
potentially novel class of therapeutic
agents for type 2 diabetes” (2).
Although the carefully performed
study by Kim et al. provides new
insight into the mechanisms of fat-
induced insulin resistance, we would
like to caution against the preliminary
conclusion concerning beneficial
effects of salicylates on insulin resist-
ance. First of all, in contrast to the
findings of Kim et al. in the triglyc-
eride (TG) infusion model in the rat,
earlier studies in human volunteers
using hyperglycemic clamp techniques
reported increased insulin resistance
by salicylate compounds (3, 4). These
findings suggest that the effects of sal-
icylates may depend on the experi-
mental model, and possibly on the
species studied.
There are also strong theoretical
arguments that salicylates have dele-
terious effects on insulin resistance.
Similar to TGs (or fatty acids), the
proinflammatory cytokine TNF-α
synthesized by adipocytes is a central
factor in the pathogenesis of insulin
resistance (5). As underlined also by
Kim et al., there is significant overlap
between the intracellular events
induced by fatty acids and TNF in
insulin-sensitive tissues: both activate
IKK-β and decrease IRS-1 tyrosine
phosphorylation, and both increase
intracellular ceramide concentrations,
which leads to inhibition of Akt/pro-
tein kinase B activation and impaired
GLUT-4 translocation (these relation-
ships are outlined in Figure 1) (6–8).
The effects of salicylates on TNF-
induced insulin resistance are com-
pletely opposite to those reported by
Kim and colleagues on fat-induced
insulin resistance. TNF induces the
synthesis of prostaglandins (PGs),
which function as a negative feedback
mechanism by inhibiting the
upstream TNF production (9). We
and others have shown in healthy vol-
unteers that administration of aspirin
or indomethacin, both strong
inhibitors of PG synthesis, enhances
TNF production capacity at least
twofold (10, 11), which can negatively
affect insulin sensitivity. In addition,
PGs stimulate synthesis of leptin, an
adipocytokine known to decrease
insulin resistance through improve-
ment of IRS-1−associated phos-
phatidylinositol (PI) 3-kinase activity
(12, 13). Although not yet experimen-
tally tested, inhibition of PG synthesis
by salicylate compounds may also
negatively influence insulin sensitivi-
ty by inhibition of leptin release. Thus,
aspirin could increase insulin resist-
ance through at least two mechanisms
mediated by the inhibition of PG syn-
thesis, namely the upregulation of
TNF synthesis and the inhibition of
leptin release (Figure 1). There are
other important endogenous factors
modulating the resistance to insulin:
adiponectin reverses insulin resist-
ance, possibly in part by inhibition of
TNF synthesis, whereas resistin
impairs glucose tolerance and insulin
action (12, 14). The influence of sali-
cylates on the modulation of these
proteins is not known.
In conclusion, the influence of sali-
cylate compounds on insulin sensi-
tivity is multifactorial and involves
both beneficial and deleterious
effects. This should not preclude
patients from taking low-dose aspirin
to prevent cardiovascular disease (15),
but more basal and clinical studies
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Figure 1
The effects of salicylates on insulin resistance. There is significant overlap between the intracellular
events induced by TGs (or FFAs) and TNF regarding the mechanisms of insulin resistance. Both stim-
uli activate IKK-β and decrease insulin-induced tyrosine phosphorylation of IRS-1; both increase intra-
cellular ceramide concentrations, which leads to inhibition of Akt/protein kinase B activation and
inhibition of GLUT-4 translocation. These effects induce a state of insulin resistance. The effects of
salicylate compounds on these pathways may be divergent. That is, they may improve insulin resist-
ance by blocking the activation of IKK-β (top), or they may worsen insulin resistance by inhibiting PG
synthesis and thus potentiating TNF release (bottom). In addition, inhibition of PG will decrease syn-
thesis of leptin, which is known to improve insulin sensitivity by stimulating IRS-1–associated PI 
3-kinase activity. The beneficial effect of leptin on insulin action is thus decreased (bottom).
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Kim et al. reply — We would like to
thank Netea et al. for their thought-
ful comments regarding our article
(1). First of all, we would like to
emphasize that we are not advocating
the use of high-dose aspirin for the
treatment of type 2 diabetes. In fact,
we strongly recommend against it in
view of aspirin’s potential long-term
toxicities at high doses. Our studies
used high-dose aspirin as a pharma-
cological tool to identify IKK-β as a
potentially novel therapeutic target
for type 2 diabetes. This hypothesis,
developed by Yuan et al. (2), led to our
finding that Ikk-β–/+ mice were pro-
tected from obesity- and diet-induced
insulin resistance (2) as well as fol-
lowing 5-hour lipid infusion (1).
Because aspirin is a weak inhibitor of
IKK-β, high doses of the drug restore
insulin sensitivity in each of these
models of insulin resistance.
We are aware of the previous studies
that have shown that aspirin therapy
actually causes insulin resistance (3–5).
We believe the major reason for the
discrepancy is not due to species dif-
ferences as suggested by Netea et al.
but rather the lower dose and duration
of salicylate therapy used in these
human studies. Even older clinical tri-
als clearly showed hypoglycemic
effects of high doses (4–10 g/day) of
aspirin and salicylate that occur pro-
gressively over 1 to 2 or 3 weeks (6).
Using corresponding therapeutic reg-
imens, we saw beneficial effects in
rodents (1, 2) and, in more recent stud-
ies by our group, in humans (7). High-
dose salicylate treatment (about 7
g/day for 2 weeks) was very successful
in lowering fasting and postprandial
hyperglycemia in patients with type 2
diabetes, which could partly be attrib-
uted to increased peripheral insulin
sensitivity as assessed by a hyperinsu-
linemic-euglycemic clamp (7).
In summary, we believe that our data
(1) support the hypothesis that fat
induces insulin resistance through
activation of a serine/threonine kinase
cascade leading to decreased IRS-
1/IRS-2–associated phosphatidylinos-
itol 3-kinase activity in muscle and
liver (2, 8), and that IKK-β, and the
steps leading to its activation, are
potential novel therapeutic targets for
type 2 diabetes mellitus.
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